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ABSTRACT
Introduction: Targeting small airway inflam-
mation could lead to improved clinical out-
comes in asthma. Previous observational studies
concluded that therapy with extrafine-particle
[mass median aerodynamic diameter (MMAD)
\2 lm] inhaled corticosteroids (ICS) is associ-
ated with similar or better odds of achieving
asthma control at lower prescribed doses than
fine-particle ICS (MMAD = 2–5 lm). However,
while it is believed that the dose–response for
ICS reaches a plateau at sub-maximal doses, it is
not clear whether such a plateau occurs with
extrafine-particle ICS.
Methods: To evaluate the potential effect of ICS
particle size on dose–response of asthma-related
outcomes, we studied severe exacerbation rates
in a historical patient cohort of UK adults and
adolescents with asthma initiating extrafine- or
fine-particle ICS. We extracted electronic med-
ical record data centralized at primary care
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practices, where information from secondary
care and hospitalizations is also aggregated.
Data were collected over one baseline (pre-ini-
tiation) and one outcome year.
Results: Of 32,235 patients with asthma (aged
12–80 years), 54% initiated ICS with
extrafine-particle ICS and 46% with fine-particle
ICS. Overall, mean age (SD) was 41 (17) years;
60% female; 24% current and 20% ex-smokers.
We found a greater (P\0.001) reduction in
exacerbation rate at higher as compared with
lower doses of extrafine-particle ICS: for
patients initiating on B125 lg/day the reduc-
tion was -0.016 (95% CI -0.038, 0.006) exac-
erbations per year and for those initiating on
[250 lg/day the reduction was -0.072 (-0.095,
-0.049). No significant dose–response relation-
ship was observed for patients initiating on
fine-particle ICS [reduction in exacerbations per
year: -0.041 (-0.070, -0.012) at the lowest
doses and 0.009 (-0.017, 0.036) at the highest,
P = 0.856, despite similar exacerbation rates in
the baseline period for both cohorts (P = 0.40)].
Conclusion: Our findings suggest that
extrafine-particle ICS is associated with a
reduction in exacerbation rates in a dose-de-
pendent fashion in an adult asthma population.
This dose–response relationship was not
observed with fine-particle ICS.
ENCePP Trial Registration: EUPAS8840.




Asthma is a heterogeneous disease characterized
by chronic inflammation and remodeling of the
airways. There is compelling evidence that both
central and peripheral airway inflammation are
involved in this disease. Peripheral airways are
defined as those that have an internal diameter of
\2 mm, do not contain cartilage in their walls,
and extend to the alveolar ducts. Peripheral lung
inflammation has been found in patients with
mild asthma and has been suggested to play a
part in the clinical expression and worse control
of asthma [1]. The outer wall of peripheral
airways has recently been recognized as the
major site of remodeling in patients with fatal
asthma [2]. Moreover, early closure of peripheral
airways has been shown to characterize patients
with ‘‘difficult to control’’ asthma [3].
International guidelines affirm inhaled cor-
ticosteroids (ICS) as the mainstay of pharma-
cological asthma treatment [4], as they reduce
eosinophilic inflammation, improve pulmonary
function, and lead to reduction in symptoms
and exacerbations. Studies examining fine-par-
ticle ICS have indicated a relatively flat
dose–response of ICS with respect to clinical
outcomes, including exacerbations [5, 6]. Most
of the therapeutic benefits of ICS in patients
with mild to moderate asthma are achieved at
relatively low doses, equivalent to 100–250 lg
fluticasone propionate per day, with a maxi-
mum achievable benefit at around 500 lg/day
[6, 7]. Randomized controlled trials (RCTs) have
found that low dose ICS is as effective as high
dose ICS at achieving asthma control [8].
However, lack of data limits these findings due
to paucity of dose response studies. Since
fine-particle ICS effectively reduce inflamma-
tion in the larger airways, but may not reach the
peripheral airways, this plateau in dose–re-
sponse might be due, at least partially, to
residual inflammation in the small airways [9].
Inflammatory and structural changes occur
throughout the airways. Therefore, anti-in-
flammatory treatment should be targeted at
both central and peripheral airways to achieve
inflammation suppression throughout the
bronchial tree.
The effect of inhalation therapy is deter-
mined by multiple factors, including the
amount of therapy reaching the lungs and its
distribution throughout the airways [10]. Tar-
geting inhaled drug formulations to the
peripheral airways is not efficient, with most of
the formulations being deposited in the central
airways. A way to overcome this is to reduce the
mean particle size of the inhaled drug to a mass
median aerodynamic diameter (MMAD) of
\2 lm. As particle size decreases, the fraction
reaching the peripheral areas of the lung
increases [11]. Drug formulations that have a
small particle size are called extrafine, and RCTs
have shown that, when prescribed as a single
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therapy, extrafine ICS provide additional clini-
cal benefits compared with the same fine-parti-
cle therapy or placebo [12, 13].
Extra-fine-particle dose–response may continue
beyond that of fine-particle ICS therapy owing
to greater peripheral lung deposition [14]. This
hypothesis is supported by real-life research
reporting similar, or in some instances signifi-
cantly better, asthma control outcomes with
extrafine drug formulations compared with
fine-particle ones, and at a lower dose [15, 16].
Using nationwide databases to conduct real-life
studies allows the generation of large and
heterogeneous populations of patients with
asthma. This permits us to examine longer-term
outcomes, providing information to comple-
ment the results of RCTs through the inclusion
of unselected representative patients managed
in real-life clinical practice [17–19]. Thus,
exploring the dose–response relationship of
extrafine versus fine-particle ICS may have
clinical implications but may also provide
insights on the clinical relevance of the ‘‘distal
airways inflammation’’ concept. The aim of this
study was to investigate the hypothesis that the
dose–response effect on the change in the rate
of severe asthma exacerbations is steeper for
extrafine particle ICS than for fine-particle ICS
in a real-life dataset.
METHODS
Study Design
This historical, within-treatment cohort analy-
sis consisted of a 1-year baseline period for
patient characterization, followed by a 1-year
outcome evaluation period. The baseline and
outcome periods were separated by the index
date. The index date was defined as when
patients received their first prescription of ICS
as either extrafine-particle ICS [hydrofluo-
roalkane beclomethasone diproprionate (EF
HFA-BDP; Qvar) or ciclesonide (Alvesco)] or
fine-particle ICS [fluticasone propionate (FP) or
fine-particle beclomethasone dipropionate
(BDP) (Clenil)].
The study protocol was designed prior to
data extraction by an independent steering
committee and registered with the European
Network of Centers for Pharmacoepidemiology
and Pharmacovigilance (trial registration num-
ber EUPAS8840).
Data Source
The study utilized two large UK primary care
databases, the Optimum Patient Care Research
Database (OPCRD) [20] and the Clinical Practice
Research Datalink (CPRD) [21]. At the time of
the study, the OPCRD contained anonymous,
longitudinal data for over 84,534 patients with
asthma. The OPCRD is approved by the Health
Research Authority of the UK NHS for clinical
research use (REC reference: 15/EM/0150). The
CPRD is the world’s largest validated computer-
ized database of anonymized longitudinal med-
ical records for primary care [22]. At the time of
the study, data were available for approximately
13 million patient records from over 450 primary
care practices throughout the UK. Records con-
tain complete prescribing and coded diagnostic
and clinical information as well as information
on tests requested, laboratory results and refer-
rals made at, or following on from, each con-
sultation [23]. This was a retrospective study
utilizing anonymized patient data, for which
formal consent is not required.
Patients
Eligible patients were aged 12 to 80 years with
mild to moderate asthma, received C2 asthma
prescriptions during the outcome year (i.e., C1
in addition to the ICS prescription at the index
date), initiated ICS as a single therapy, and had
2 years of continuous practice data (comprising
C1 year of baseline data and 1 year of outcome
data). Patients were excluded if they had a
diagnosis for any chronic respiratory disease
other than asthma at any time in their records,
received maintenance oral corticosteroids dur-
ing the baseline year, received a co-prescription
for a long-acting beta-agonist (LABA), leuko-
triene receptor antagonist (LTRA), or theo-
phylline, and were a smoker or ex-smoker over
the age of 60 (to minimize the risk of including
patients with COPD).
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Outcome Measures
The primary endpoint was severe asthma exac-
erbation rate. We evaluated outcomes for three
ICS dose categories (B125 lg/day, 125–
250 lg/day,[250 lg/day FP equivalent) in each
arm (fine and extrafine particles). We plotted
the absolute change in severe exacerbations
from baseline to outcome. We defined a severe
exacerbation as an asthma-related hospital
admission, emergency department attendance,
or an acute course of oral corticosteroids (based
on the American Thoracic Society/European
Respiratory Society definition) [24]. Asthma
treatment guidelines recommend that
extrafine-particle ICS [i.e., ciclesonide
(Alvesco) and extrafine-particle hydrofluo-
roalkane beclomethasone dipropionate (EF
HFA-BDP; Qvar)] are prescribed at the same
dose as fine-particle fluticasone propionate (FP)
(e.g. 100 lg = 100 lg), and at half the dose of
fine-particle beclomethasone suspension
(100 lg BDP = 50 lg FP) [25].
Statistical Analysis
Summary statistics for all baseline and outcome
variables were generated to characterize patients
in each ICS dose category. We used the
Mann–Whitney test for continuous variables
and the Chi square test for categorical variables
to compare treatment groups at baseline; and
the Kruskal–Wallis Test to identify the differ-
ences in exacerbation rates by dose. Doses were
expressed as FP equivalent. Statistically signifi-
cant results were defined as P\0.05. The mean
and 95% confidence interval of the change in
exacerbation rate from baseline to outcome for
three ICS dose categories was plotted.
No prospective power calculation was carried
out since the sample size was determined by the
number of eligible patients in the OPCRD per
the inclusion criteria.
All analyses were carried out using IBM SPSS
Statistics version 21 (IBM SPSS Statistics, Fel-
tham, Middlesex, UK), SAS version 9.3 (SAS
Institute, Marlow, Buckinghamshire, UK), and




We identified 508,349 patients of whom 32,235
met the study eligibility criteria (Figure S1,
online supplement). Of these, 17,023 (53%)
were prescribed EF HFA-BDP (Qvar), 247
(0.8%) ciclesonide (Alvesco), 4693 (15%) FP via
pMDI, 3046 (9%) FP via DPI, and 7226 (22%)
fine-particle beclomethasone dipropionate
(Clenil).
The mean age (SD) of the total population
was 41 (17) years, 60% were female, and 44%
were current or ex-smokers (under the age of
60). Baseline exacerbation rates were compara-
ble for patients initiating on extrafine- and
fine-particle ICS (P = 0.40) (Table 1). Peak expi-
ratory flow was also similar between patients
initiating on fine or extrafine (P = 0.309;
Table 1). The higher dose categories had greater
proportions of patients with 1 or [2 baseline
exacerbations, compared with the lowest dose
category, which was consistent across both the
extrafine- and fine-particle groups (Table 2).
Outcomes
Using the Kruskal–Wallis test we found there
was a significant difference in the primary study
endpoint, rate of severe exacerbations, between
the dose categories of ICS for both extrafine-
and fine-particle cohorts (Fig. 1). There was a
greater (P\0.001) reduction in exacerbation
rate at higher doses of extrafine-particle ICS
compared with lower and medium doses (Fig. 1;
Table 3). Specifically, for patients initiating on
B125 lg/day the reduction was -0.016 (95% CI,
-0.038, 0.006) exacerbations per year. For those
initiating on[125–250 lg/day of extrafine-par-
ticle ICS, the reduction was -0.423 (95% CI,
-0.057, -0.028) and for those initiating on
[250 lg/day the reduction was -0.072 (95% CI,
-0.095, -0.049). An increasing dose–response
relationship was not observed for patients ini-
tiating on fine-particle ICS. There were signifi-
cant reductions in exacerbations per year in the
lowest dose category [-0.041 (95% CI, -0.070,
-0.012)], and the medium dose category
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Age (years), mean (SD) 41.5 (16.4) 39.9 (17.0) 40.8 (16.7) \0.001*
Female, n (%) 10,395 (60.2) 9055 (60.5) 19,450 (60.3) 0.562¥
Recorded smoking status, n (%)
Non-smoker 9046 (52.4) 8471 (56.6) 17,517 (54.3)
Current smoker 4303 (24.9) 3329 (22.2) 7632 (23.7) \0.001¥
Ex-smoker 3577 (20.7) 2835 (18.9) 6412 (19.9)
Unknown 344 (2.0) 330 (2.2) 674 (2.1)
Percent predicted peak ﬂow readings (%), mean
(SD)
83.58 (19.01) 83.29 (19.70) 83.45 (19.33) 0.309*
N (% non-missing) 11,863 (63.8) 11,175 (58.1) 23,038 (60.9)





ICS dose (lg), mean (SD) 238.1 (116.7) 343.0 (288.9) 286.8 (220.8) \0.001*
Severe exacerbations during baseline year (ATS/ERS deﬁned), n (%)
0 14,182 (82.1) 12,248 (81.8) 26,430 (82.0)
1 2518 (14.6) 2149 (14.4) 4667 (14.5) 0.052¥
C2 570 (3.3) 568 (3.8) 1138 (3.5)
Average SABA daily dose (lg)
None, n (%) 7533 (43.6) 6499 (43.4) 14,032 (43.5)
B100, n (%) 4332 (25.1) 3495 (23.4) 7827 (24.3) \0.001¥
101–200, n (%) 2951 (17.1) 2618 (17.5) 5569 (17.3)
[200, n (%) 2454 (14.2) 2353 (15.7) 4807 (14.9)
Risk domain asthma control, n (%) 11,801 (68.3) 10,405 (69.5) 22,206 (68.9) 0.021¥
GERD diagnosis or therapy, n (%) 3607 (20.9) 3183 (21.3) 6790 (21.2) 0.399¥
IHD diagnosis, n (%) 777 (4.5) 545 (3.6) 1322 (4.1) \0.001¥
Rhinitis diagnosis or therapy, n (%) 5016 (29.0) 4830 (32.3) 9846 (30.5) 0.011¥
SD standard deviation, GERD gastroesophageal reﬂux disease, IHD ischemic heart disease, SABA short-acting beta agonist,
ICS inhaled corticosteroid, LABA long-acting beta agonist
* Mann–Whitney test
¥ Chi squared test
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[-0.0188 (95% CI, -0.035, -0.027)], but not in
the highest dose category [0.009 (95% CI,
-0.017, 0.036); Fig. 1, Table 3].
DISCUSSION
This real-life asthma patient population study
found an increasing dose–response relationship
between extrafine ICS and reduction in exacer-
bation rates in adolescent and adult patients
initiated on ICS. However, for patients receiving
fine-particle ICS, high doses were not more
beneficial than lower doses.
These findings reinforce previous studies in
which EF HFA-BDP had a similar or better
chance of achieving asthma control than fluti-
casone [16, 26, 27]. The superior effectiveness of
Table 2 Baseline characteristics for patients initiated on different doses of extraﬁne- and ﬁne-particle ICS
Extraﬁne-particle ICS daily
dose at initiationa (lg)
Fine-particle ICS daily
dose at initiationa (lg)
Characteristic >0–125 >125–250 >250 P value >0–125 >125–250 >250 P value
N (%) patients 3211 (18.6) 9384 (54.3) 4675 (27.1) 2073 (13.9) 7754 (51.8) 5138 (34.3)
Age, mean (SD) 38.2 (17.2) 41.2 (16.4) 44.3 (15.5) 33.5 (18.0) 39.2 (16.9) 43.5 (15.7)
Female sex, n (%) 2054 (64.0) 5625 (59.9) 2716 (58.1) 1245 (60.1) 4722 (60.9) 3088 (60.1)
Severe exacerbations during baseline year, n (%)
0 2763 (86.0) 7766 (82.8) 3653 (78.1) 1738 (83.8) 6407 (82.6) 4103 (79.9)
1 363 (11.3) 1337 (14.2) 818 (17.5) \0.001* 270 (13.0) 1085 (14.0) 794 (15.5) \0.001*
[2 85 (2.6) 281 (3.0) 204 (4.4) 65 (3.1) 262 (3.4) 241 (4.7)
SD standard deviation
* Chi squared test
a Fluticasone propionate equivalent
Fig. 1 Mean change in the severe exacerbation rate (ATS/
ERS deﬁned) from baseline to outcome versus ICS dose
prescribed at index date for the adult initiation cohort.
Note: Exacerbation rate from baseline year to outcome
year was compared using the Kruskal–Wallis test. IPD
Index Prescription Date, ICS Inhaled Corticosteroids, FP
Fluticasone Propionate, CI Conﬁdence Interval, ATS
American Thoracic Society, ERS European Respiratory
Society
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extrafine-particle ICS observed in this study
may be explained by improved airway drug
deposition and distribution. The results of the
present study add to the evidence in support of
the use of extrafine-particle ICS to treat small
airway inflammation [26, 28, 29].
A non-randomized, open-label study, using
scintigraphic assessment, demonstrated that
50% of the ex-actuator dose of ciclesonide
extrafine particles was deposited in the lungs,
and that the highest deposition occurred in the
peripheral regions containing the small airways
[30]. 3D SPECT imaging revealed that the
highest deposition occurred within the periph-
eral regions of the lung that contain the small
airways and alveoli and low oropharyngeal
deposition [30]. The authors concluded that
this combination may contribute to the reduced
incidence of side effects associated with cicle-
sonide use. Inflammation and patency of small
airways was shown to improve with ciclesonide
suggesting that it exerts an anti-inflammatory
effect on small airways [13]. A real-world pilot
study by Hodgson et al. [31] found that, in
patients with severe asthma, there was signifi-
cantly less airway eosinophilia with ciclesonide
than with placebo. In addition to improved
asthma control, effective targeting of the small
airways, at a lower dose, may have the potential
to reduce local and systemic side effects [32].
There is increasing evidence to support the
hypothesis that small airway inflammation
contributes to difficulties in asthma control and
that extrafine ICS can control this. This may
also explain why the effect of increasing dose of
patients initiating on fine-particle ICS is less
steep than that seen with the extrafine ICS.
Distal lung disease has been associated with a
risk of recurrent asthma exacerbations [32];
therefore, small airways may be important in
patients with more severe disease. These
patients are often those treated with higher
doses of ICS. The use of severe exacerbations as
the primary outcome in the present study
highlights a real-life clinical benefit of improved
small airway deposition.
RCTs are generally representative of only
fewer than 5% of all patients with asthma [33]
and have limited inclusion criteria, which often
exclude typical patients seen in general practice,
such as smokers and those with comorbidities,
and those that suffer from severe or unsta-
ble disease. Study durations are short, ranging
from six days to three months. Licensing studies
are often designed to show equivalence and
often take stable populations. The differences in
efficacy between RCTs and real-world studies
could be partly due to high adherence in such
studies, due to constant monitoring of the
patient. Adherence is a prerequisite for enrol-
ment into RCTs to maximize the treatment
effects. Patients enrolled in studies tend to pay
closer attention to their health and are more
likely to follow instructions. This does not
reflect the situation in the general patient pop-
ulation where adherence tends to be relatively
low [34]. The generalizable nature of these
findings has the potential to inform future
Table 3 Outcome characteristics for patients initiated on different doses of extraﬁne- and ﬁne-particle ICS
Extraﬁne-particle ICS





Characteristic >0–125 >125–250 >250 P value >0–125 >125–250 >250 P value
Severe exacerbations during outcome year, n (%)
0 2864 (89.2) 8281 (88.2) 3986 (85.3) 1807 (87.2) 6684 (86.2) 4303 (83.7)
1 253 (7.9) 804 (8.6) 499 (10.7) \0.001* 209 (10.1) 800 (10.3) 563 (11.0) \0.001*
[2 94 (2.9) 299 (3.2) 190 (4.1) 57 (2.7) 270 (3.5) 272 (5.3)
* Chi squared test
a Fluticasone propionate equivalent
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changes in practice and thus have an early
clinical impact. Therefore, evidence from real-
world studies is an important addition to evi-
dence from RCTs.
As with other observational studies, there is a
potential for selection and physician bias and
residual confounding. Furthermore, the analysis
was based on the prescribed dose at ICS initia-
tion, as opposed to ICS doses during the out-
come year. In this observational study the
response to consumed dose would not be a
meaningful analysis as the results would there-
fore be confounded by severity. We relied on
prescription information from the primary care
databases we used. This was an inten-
tion-to-treat analysis, thus the data allowed us
to identify instances of when prescriptions were
written by GPs. It did not include information
on whether the prescription was filled, and thus
we are unable to guarantee consumption of the
medications in this study. However, this does
not rule out that the relationship between ini-
tial severity and dose response efficacy is
attributable to decreased responsiveness at
lower doses among patients with more severe
asthma [35], rather than to increased respon-
siveness to medication. Study findings are
dependent on the availability and quality of the
data in the OPCRD and CPRD, which contain
limited information on hospitalizations.
At the time of this study both ciclesonide
and EF HFA-BDP were prescribed for treatment
of asthma in the UK. Although we did not
specifically look at how many of the patients
examined were on different EF ICS preparations,
most patients in the UK, at the time of this
study, prescribed extrafine ICS were given
beclomethasone, not ciclesonide. A recent
publication has shown that ciclesonide and EF
HFA-BDP have similar potency and that once-
daily dosing of beclomethasone and ciclesonide
is similar in efficacy [36]. It is therefore unlikely
for individual drug type to have a significant
effect on the outcomes.
A measure of exhaled nitric oxide would
allow a more concrete evaluation of the effect of
treatment on the peripheral airways, as this has
previously been reported to decrease upon use
of EF-BDP compared with the non-extrafine
formulation [37]. Nonetheless, the OPCRD is
accepted as a high-quality database with the
advantages of large size and inclusion of a rep-
resentative sample of the UK population. The
use of patient-centered severe exacerbations as
the primary outcome further strengthens this
study. Evaluation over one full baseline year
and one full outcome year was done to ensure
minimal effect of seasonal variations as well as
ensure recording of any infrequent outcomes,
such as exacerbations. The inclusion and
exclusion criteria were selected to minimize
potential confounding factors such as other
asthma pharmacotherapies, and to identify
patients from a large clinical population
receiving initial ICS therapy.
CONCLUSIONS
In a real-life population of adult patients with
asthma initiating ICS therapy, patients starting
with higher doses of extrafine-particle size ICS
had a greater reduction in severe exacerbation
rates, compared with those initiating on low or
medium doses. This dose–response effect was
not observed with initiation of fine-particle ICS.
This supports the hypothesis that targeting the
small airways, using extrafine-particle ICS, may
improve the dose–response to inhaled corticos-
teroids in asthma. Further prospective observa-
tional studies and pragmatic trials are needed to
confirm this hypothesis.
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